> top > projects > sentences > docs > PubMed:26094080 > annotations
sentences Home  

PubMed:26094080 JSONTXT 7 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-6 Sentence denotes CHAMP:
T1 0-6 Sentence denotes CHAMP:
TextSentencer_T2 7-239 Sentence denotes A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status.
T2 7-239 Sentence denotes A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status.
TextSentencer_T3 240-253 Sentence denotes INTRODUCTION:
T3 240-253 Sentence denotes INTRODUCTION:
TextSentencer_T4 254-608 Sentence denotes The aim of the study was to investigate the efficacy and tolerability of panitumumab, a fully human antiepidermal growth factor receptor monoclonal antibody, in combination with pemetrexed/cisplatin in patients with stage IIIB to IV primary nonsquamous non-small-cell lung cancer and wild type V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS).
T4 254-608 Sentence denotes The aim of the study was to investigate the efficacy and tolerability of panitumumab, a fully human antiepidermal growth factor receptor monoclonal antibody, in combination with pemetrexed/cisplatin in patients with stage IIIB to IV primary nonsquamous non-small-cell lung cancer and wild type V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS).
TextSentencer_T5 609-731 Sentence denotes Results were compared with those obtained in a control group of patients who received a pemetrexed/cisplatin regimen only.
T5 609-731 Sentence denotes Results were compared with those obtained in a control group of patients who received a pemetrexed/cisplatin regimen only.
TextSentencer_T6 732-753 Sentence denotes PATIENTS AND METHODS:
T6 732-753 Sentence denotes PATIENTS AND METHODS:
TextSentencer_T7 754-826 Sentence denotes This was a phase II, randomized, open-label study with 2 treatment arms.
T7 754-826 Sentence denotes This was a phase II, randomized, open-label study with 2 treatment arms.
TextSentencer_T8 827-1007 Sentence denotes In total, 96 patients received panitumumab at a dose of 9 mg/kg in combination with pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) (n = 49) or pemetrexed/cisplatin alone (n = 47).
T8 827-1007 Sentence denotes In total, 96 patients received panitumumab at a dose of 9 mg/kg in combination with pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) (n = 49) or pemetrexed/cisplatin alone (n = 47).
TextSentencer_T9 1008-1078 Sentence denotes The primary outcome measure was progression-free survival at 6 months.
T9 1008-1078 Sentence denotes The primary outcome measure was progression-free survival at 6 months.
TextSentencer_T10 1079-1193 Sentence denotes Secondary end points of the study included overall survival, tumor response, quality of life, and safety outcomes.
T10 1079-1193 Sentence denotes Secondary end points of the study included overall survival, tumor response, quality of life, and safety outcomes.
TextSentencer_T11 1194-1268 Sentence denotes The CHAMP study is registered with ClinicalTrials.gov, number NCT01088620.
T11 1194-1268 Sentence denotes The CHAMP study is registered with ClinicalTrials.gov, number NCT01088620.
TextSentencer_T12 1269-1277 Sentence denotes RESULTS:
T12 1269-1277 Sentence denotes RESULTS:
TextSentencer_T13 1278-1539 Sentence denotes Progression-free survival at 6 months did not indicate a benefit of panitumumab as a supplement to the standard therapy of pemetrexed/cisplatin whereas the overall survival showed a clear difference between the treatment groups in favor of the standard therapy.
T13 1278-1539 Sentence denotes Progression-free survival at 6 months did not indicate a benefit of panitumumab as a supplement to the standard therapy of pemetrexed/cisplatin whereas the overall survival showed a clear difference between the treatment groups in favor of the standard therapy.
TextSentencer_T14 1540-1662 Sentence denotes Results might be affected by the higher rates of serious adverse events and higher death rates within the panitumumab arm.
T14 1540-1662 Sentence denotes Results might be affected by the higher rates of serious adverse events and higher death rates within the panitumumab arm.
TextSentencer_T15 1663-1675 Sentence denotes CONCLUSIONS:
T15 1663-1675 Sentence denotes CONCLUSIONS:
TextSentencer_T16 1676-2069 Sentence denotes Results from the present study indicate that combination of cisplatin/pemetrexed with panitumumab should not be recommended for patients with adenocarcinoma and KRAS wild type because of lack of efficacy, lack of improvement of quality of life, and because of the increase in toxicity rates compared with patients in the control arm, who received standard chemotherapy of pemetrexed/cisplatin.
T16 1676-2069 Sentence denotes Results from the present study indicate that combination of cisplatin/pemetrexed with panitumumab should not be recommended for patients with adenocarcinoma and KRAS wild type because of lack of efficacy, lack of improvement of quality of life, and because of the increase in toxicity rates compared with patients in the control arm, who received standard chemotherapy of pemetrexed/cisplatin.